Under this year’s theme of ‘Kidney Health For All’, ISN along with AstraZeneca aims to generate large scale awareness and educate people about ways to improve kidney health
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Approximately five kg tumor was removed in the eight-hour long complicated surgery
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
The hospital works in close collaboration with the Network for Organ Sharing and the National Organ & Tissue Transplant Organisation (NOTTO) and it is amongst the very few hospitals doing ABO-incompatible transplant
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Subscribe To Our Newsletter & Stay Updated
